Is aripiprazole (Abilify) 2 mg once daily safe for a patient with an estimated glomerular filtration rate of 12 mL/min?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Aripiprazole 2 mg Once Daily is Safe for eGFR 12 mL/min

Based on FDA labeling, no dose adjustment of aripiprazole is required for any degree of renal impairment, including severe renal dysfunction with eGFR as low as 12 mL/min. 1

Direct FDA Guidance on Renal Impairment

The FDA-approved prescribing information for Abilify (aripiprazole) explicitly states: "No dosage adjustment for ABILIFY is required on the basis of a patient's renal function (mild to severe renal impairment, glomerular filtration rate between 15 and 90 mL/minute)" 1. This recommendation is based on pharmacokinetic studies demonstrating that aripiprazole clearance is not significantly altered by renal dysfunction.

Supporting Pharmacokinetic Evidence

A dedicated pharmacokinetic study in patients with severe renal impairment (creatinine clearance <30 mL/min) found no meaningful differences in aripiprazole exposure compared to those with normal renal function 2. Specifically:

  • The area under the curve (AUC) was actually approximately 19% lower in renally impaired subjects
  • Renal clearance of aripiprazole was negligible (0.04 mL/h/kg in controls), confirming that the kidneys play a minimal role in drug elimination
  • Aripiprazole is primarily metabolized hepatically via CYP3A4 and CYP2D6, not renally excreted 3, 4

Clinical Considerations for This Patient

The 2 mg dose is actually below the typical therapeutic range (10-30 mg/day for schizophrenia) 5, 3, which provides an additional safety margin. At this low dose with eGFR 12:

  • No dose reduction is needed - the standard dose would already be safe
  • Monitor for typical aripiprazole side effects (akathisia, insomnia, nausea) rather than renal-specific concerns
  • The drug's long half-life (75 hours) means steady state takes 14 days regardless of renal function 3, 4

Important Caveats

While renal impairment doesn't require dose adjustment, consider:

  • Hepatic function - if liver disease coexists, this could affect metabolism, though even severe hepatic impairment doesn't require dose adjustment per FDA labeling 1
  • CYP2D6 poor metabolizers - approximately 8% of Caucasians require dose reduction to half the usual dose due to genetic polymorphism 1, unrelated to renal function
  • Drug interactions - avoid strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin) which reduce efficacy 1

Bottom line: Proceed with aripiprazole 2 mg daily without modification for the eGFR of 12 mL/min.

References

Related Questions

In a patient with an eGFR of 42 mL/min/1.73 m², which of the following medications require dose adjustments: famotidine 20 mg, adalimumab 30 mg, calcitriol 0.5 µg, atorvastatin 10 mg, venlafaxine 37.5 mg, vitamin D3 2400 IU, and calcium carbonate 18 mg?
Is a 2 mg dose of Abilify (aripiprazole) appropriate for a patient with impaired renal function?
A 43-year-old patient has been taking aripiprazole (Abilify) 2 mg daily for about two months, experienced improvement for a few weeks, but now reports no noticeable benefit—what should be the next step in management?
An 86-year-old patient with an estimated glomerular filtration rate of 28 mL/min/1.73 m² is taking pregabalin 50 mg once daily; should the pregabalin dose be adjusted?
In an 88-year-old patient with an estimated glomerular filtration rate of 28 mL/min/1.73 m² who is taking omeprazole 20 mg daily, does the medication require renal dose adjustment?
What assessment questions should be asked of a patient presenting for HIV pre‑exposure prophylaxis (PrEP) evaluation?
What are the risks and benefits of catheter ablation for symptomatic atrial fibrillation in an adult patient who has failed or cannot tolerate at least one anti‑arrhythmic drug?
What is the appropriate hydroxyzine (Atarax) dose for a child weighing 22.4 kg?
What is the differential diagnosis and appropriate evaluation for a patient presenting with leukopenia, low hematocrit, elevated mean corpuscular volume (MCV), and decreased mean corpuscular hemoglobin concentration (MCHC)?
Is it appropriate to assume COVID-19 when flu-like symptoms persist for more than seven days?
What is the significance of a 4‑month‑old infant having a 10‑hour period without a wet diaper followed by bright orange urine, and what immediate evaluation and management are recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.